Cellular Intelligence Appointed New Advisory Board
The Boston-based startup has recruited four industry leaders to guide its AI-driven cell behavior research.
Updated on Sept. 21, 2026 in Artificial Intelligence
Live Poll
Do you believe integrating AI into medical research will effectively lower the cost of new medicines?
Cellular Intelligence has appointed Robert Langer, Yann LeCun, Jens Nielsen, and Fabian Theis to its scientific advisory board. The company leverages AI models to predict and control cellular behavior for faster drug discovery.
Why it matters
The company aims to replace traditional trial-and-error laboratory research with AI-driven models that predict biological data, potentially lowering the costs and time required for new drug development.
Cellular Intelligence uses a proprietary engine to feed cell signal responses into AI models, which then generate biological data for its foundation models. The company has raised over $70 million in capital since its 2023 founding.
The players
Robert Langer
He is a co-founder of Moderna who holds over 1,500 patents and has joined the company board as an observer.
Yann LeCun
A recipient of the 2018 ACM A.M. Turing Award for his work in deep learning, he left Meta in 2025.
Jens Nielsen
He is a prominent scientist associated with the BioInnovation Institute in Copenhagen.
Fabian Theis
He is a researcher based at Helmholtz Munich who focuses on computational biology.
Novo Nordisk
This multinational pharmaceutical company retains an equity stake in Cellular Intelligence.
The details
Formerly operating as Somite.ai, the Boston-based firm is developing foundation models specifically for cell biology. In addition to the board appointments, co-founder of Moderna Robert Langer has joined the company board of directors as an observer.
Timeline
Cellular Intelligence was founded in 2023.
Novo Nordisk shuttered its cell-therapy division in October 2025.
Yann LeCun departed Meta in December 2025.
The firm acquired global rights to STEM-PD in May 2026.
The new advisory board members were announced on September 14, 2026.
The Tech Race
Cellular Intelligence is positioning itself within the burgeoning field of generative biology by applying foundation models to the STEM-PD Parkinson's therapy. This shift mirrors the broader transition where pharmaceutical discovery increasingly relies on predictive AI over manual, lab-heavy workflows.
While this news concerns corporate strategy, the successful application of these models could eventually lead to faster and more affordable drug development for complex conditions. For now, the integration of high-profile advisors signals the firm's focus on scaling its biological data engine.
The takeaway
The infusion of top-tier academic expertise into this startup signals an ongoing effort to bridge the gap between AI computational power and physical biological experimentation. This trend suggests that future drug breakthroughs will likely depend on the synergy between foundation models and clinical validation.
Further reading
Learn more about the latest innovations in Artificial Intelligence.
Live Poll
Do you believe integrating AI into medical research will effectively lower the cost of new medicines?
